潜伏性HIV-1感染的治疗：组蛋白去乙酰化酶抑制剂的作用
Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors.
作者信息
Manson McManamy Mary E, Hakre Shweta, Verdin Eric M, Margolis David M
机构信息
Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.
出版信息
Antivir Chem Chemother. 2014 Jan 29;23(4):145-9. doi: 10.3851/IMP2551.
Abstract
Persistence of HIV-1 in latently infected CD4(+) T-cells prevents eradication in HIV-infected treated patients. Latency is characterized by a reversible silencing of transcription of integrated HIV-1. Several molecular mechanisms have been described which contribute to latency, including the establishment and maintenance of repressive chromatin on the HIV-1 promoter. Histone deacetylation is a landmark modification associated with transcriptional repression of the HIV-1 promoter and inhibition of histone deacetylase enzymes (HDACs) reactivates latent HIV-1. Here, we review the different HDAC inhibitors that have been studied in HIV-1 latency and their therapeutic potential in reactivating latent HIV-1.
摘要
潜伏感染的CD4(+) T细胞中HIV-1的持续存在阻碍了HIV感染患者的病毒清除。潜伏期的特征是整合的HIV-1转录可逆性沉默。已经描述了几种导致潜伏期的分子机制，包括在HIV-1启动子上建立和维持抑制性染色质。组蛋白去乙酰化是与HIV-1启动子转录抑制相关的标志性修饰，抑制组蛋白脱乙酰酶（HDAC）可重新激活潜伏的HIV-1。在此，我们综述了在HIV-1潜伏期研究的不同HDAC抑制剂及其在重新激活潜伏HIV-1方面的治疗潜力。
相似文献
1
Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors.潜伏性HIV-1感染的治疗：组蛋白去乙酰化酶抑制剂的作用
Antivir Chem Chemother. 2014 Jan 29;23(4):145-9. doi: 10.3851/IMP2551.
2
Reactivation of latent HIV by histone deacetylase inhibitors.组蛋白去乙酰化酶抑制剂使潜伏 HIV 重新激活。
Trends Microbiol. 2013 Jun;21(6):277-85. doi: 10.1016/j.tim.2013.02.005. Epub 2013 Mar 18.
3
The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.组蛋白去乙酰化酶抑制剂伏立诺他（SAHA）通过加快病毒进入后事件的动力学并提高其效率，增加未感染的CD4 + T细胞对HIV的易感性。
J Virol. 2014 Sep;88(18):10803-12. doi: 10.1128/JVI.00320-14. Epub 2014 Jul 9.
4
Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency.苔藓抑素-1与组蛋白脱乙酰酶抑制剂协同作用，使潜伏的HIV-1重新激活。
Curr HIV Res. 2010 Sep;8(6):418-29. doi: 10.2174/157016210793499312.
5
Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors.新型且选择性的组蛋白去乙酰化酶抑制剂可诱导潜伏型人类免疫缺陷病毒 1 的表达。
AIDS. 2009 Sep 10;23(14):1799-806. doi: 10.1097/QAD.0b013e32832ec1dc.
6
Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells.组蛋白去乙酰化酶抑制剂：与潜伏感染细胞中 HIV 型 1（HIV-1）再激活的同种型特异性相关性。
J Biol Chem. 2011 Jun 24;286(25):22211-8. doi: 10.1074/jbc.M110.180224. Epub 2011 Apr 29.
7
Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies.HIV-1 整合后潜伏的分子调控：对新治疗策略发展的启示。
Retrovirology. 2009 Dec 4;6:111. doi: 10.1186/1742-4690-6-111.
8
Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1.新型组蛋白去乙酰化酶抑制剂 CG05 和 CG06 可有效重新激活潜伏感染的 HIV-1。
AIDS. 2010 Feb 20;24(4):609-11. doi: 10.1097/QAD.0b013e328333bfa1.
9
Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.1类选择性组蛋白去乙酰化酶（HDAC）抑制剂增强HIV潜伏逆转，同时保留最大HIV基因表达所需的HDAC亚型的活性。
J Virol. 2018 Feb 26;92(6). doi: 10.1128/JVI.02110-17. Print 2018 Mar 15.
10
Histone deacetylase inhibitor chidamide promotes reactivation of latent human immunodeficiency virus by introducing histone acetylation.组蛋白去乙酰化酶抑制剂西达本胺通过引入组蛋白乙酰化促进潜伏的人类免疫缺陷病毒的重新激活。
J Med Virol. 2018 Sep;90(9):1478-1485. doi: 10.1002/jmv.25207. Epub 2018 May 25.
引用本文的文献
1
Isoform-Selective Versus Nonselective Histone Deacetylase Inhibitors in HIV Latency Reversal.HIV 潜伏逆转中的异构体选择性与非选择性组蛋白去乙酰化酶抑制剂。
AIDS Res Hum Retroviruses. 2022 Aug;38(8):615-621. doi: 10.1089/AID.2021.0195.
2
Exhaustion and senescence of CD4 and CD8 T cells that express co-stimulatory molecules CD27 and CD28 in subjects that acquired HIV by drug use or by sexual route.通过吸毒或性途径感染艾滋病毒的受试者中，表达共刺激分子CD27和CD28的CD4和CD8 T细胞的耗竭和衰老。
Germs. 2021 Mar 15;11(1):66-77. doi: 10.18683/germs.2021.1242. eCollection 2021 Mar.
3
A transient heritable memory regulates HIV reactivation from latency.一种短暂的可遗传记忆调节潜伏状态下的HIV再激活。
iScience. 2021 Mar 9;24(4):102291. doi: 10.1016/j.isci.2021.102291. eCollection 2021 Apr 23.
4
Measuring the Success of HIV-1 Cure Strategies.评估 HIV-1 治愈策略的效果。
Front Cell Infect Microbiol. 2020 Apr 7;10:134. doi: 10.3389/fcimb.2020.00134. eCollection 2020.
5
Chorea associated with persistent low-level viremia in a patient living with HIV: a case report.一名HIV感染者中与持续性低水平病毒血症相关的舞蹈症：病例报告
J Virus Erad. 2020 Feb 20;6(1):27-29. doi: 10.1016/S2055-6640(20)30007-8.
6
Histone deacetylase 1 interacts with HIV-1 Integrase and modulates viral replication.组蛋白去乙酰化酶 1 与 HIV-1 整合酶相互作用并调节病毒复制。
Virol J. 2019 Nov 19;16(1):138. doi: 10.1186/s12985-019-1249-y.
7
Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing Platform.利用可转换 CAR-T 细胞攻击潜伏 HIV：一种高度适应性的杀伤平台。
Cell. 2019 Oct 31;179(4):880-894.e10. doi: 10.1016/j.cell.2019.10.002. Epub 2019 Oct 24.
8
Infectious Threats, the Intestinal Barrier, and Its Trojan Horse: Dysbiosis.感染威胁、肠道屏障及其特洛伊木马：肠道菌群失调
Front Microbiol. 2019 Aug 7;10:1676. doi: 10.3389/fmicb.2019.01676. eCollection 2019.
9
Application of CRISPR/Cas9-Based Gene Editing in HIV-1/AIDS Therapy.基于 CRISPR/Cas9 的基因编辑在 HIV-1/AIDS 治疗中的应用。
Front Cell Infect Microbiol. 2019 Mar 22;9:69. doi: 10.3389/fcimb.2019.00069. eCollection 2019.
10
CRISPR/Cas9 Genome Editing to Disable the Latent HIV-1 Provirus.利用CRISPR/Cas9基因编辑技术使潜伏的HIV-1前病毒失活
Front Microbiol. 2018 Dec 14;9:3107. doi: 10.3389/fmicb.2018.03107. eCollection 2018.
本文引用的文献
1
Prospects for treatment of latent HIV.潜伏 HIV 的治疗前景。
Clin Pharmacol Ther. 2013 Jan;93(1):46-56. doi: 10.1038/clpt.2012.202. Epub 2012 Oct 10.
2
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.伏立诺他治疗可打破抗逆转录病毒治疗患者的 HIV-1 潜伏。
Nature. 2012 Jul 25;487(7408):482-5. doi: 10.1038/nature11286.
3
Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradication.人类免疫缺陷病毒（HIV）潜伏期：HIV 根除的主要障碍。
Mol Med. 2012 Sep 25;18(1):1096-108. doi: 10.2119/molmed.2012.00194.
4
Molecular Understanding of HIV-1 Latency.对HIV-1潜伏的分子理解。
Adv Virol. 2012;2012:574967. doi: 10.1155/2012/574967. Epub 2012 Apr 4.
5
HIV latency: experimental systems and molecular models.HIV 潜伏期：实验系统与分子模型。
FEMS Microbiol Rev. 2012 May;36(3):706-16. doi: 10.1111/j.1574-6976.2012.00335.x.
6
A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs.一种灵活的 HIV-1 潜伏期模型，可评估许多原发性 CD4 T 细胞储库。
PLoS One. 2012;7(1):e30176. doi: 10.1371/journal.pone.0030176. Epub 2012 Jan 24.
7
Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study.丙戊酸联合高效抗逆转录病毒疗法降低系统性 HIV-1 储存库：来自一项多中心随机临床研究的结果。
HIV Med. 2012 May;13(5):291-6. doi: 10.1111/j.1468-1293.2011.00975.x. Epub 2012 Jan 26.
8
Control of HIV latency by epigenetic and non-epigenetic mechanisms.通过表观遗传和非表观遗传机制控制HIV潜伏
Curr HIV Res. 2011 Dec 1;9(8):554-67. doi: 10.2174/157016211798998736.
9
Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells.组蛋白去乙酰化酶抑制剂：与潜伏感染细胞中 HIV 型 1（HIV-1）再激活的同种型特异性相关性。
J Biol Chem. 2011 Jun 24;286(25):22211-8. doi: 10.1074/jbc.M110.180224. Epub 2011 Apr 29.
10
High-throughput screening uncovers a compound that activates latent HIV-1 and acts cooperatively with a histone deacetylase (HDAC) inhibitor.高通量筛选发现一种能激活潜伏 HIV-1 的化合物，并与组蛋白去乙酰化酶 (HDAC) 抑制剂协同作用。
J Biol Chem. 2011 Jun 17;286(24):21083-91. doi: 10.1074/jbc.M110.195537. Epub 2011 Apr 15.
Zotero 插件